Skip to main content
. Author manuscript; available in PMC: 2015 Apr 29.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Apr 16;71(5):1357–1368. doi: 10.1007/s00280-013-2136-7

Fig. 3.

Fig. 3

Synergy between bortezomib and elacridar persists in the protective effect of the BM microenvironment. Using the compartment- specific bioluminescence imaging (CS-BLI) approach, we evaluated the combination of bortezomib and elacridar on MM RPMI-Dox40-MCherry/luc cells cultured in the presence versus absence of HS-5 stromal cells and treated with bortezomib 4 and 8 nM and elacridar 0.125, 0.25 μM for 5 days. RPMI-Dox40-MCherry/luc viability was expressed as percentage (mean ± SD) compared to vehicle treated control. Experiment was repeated in triplicate. Synergistic cytotoxicity of the combination of bortezomib and elacridar persisted despite coculture with BMSCs (Δp < 0.05; *p < 0.001)